Cargando…
Therapeutic safety and efficacy of triple-immunosuppressants versus dual-immunosuppressants in severe-to-critical COVID-19: a prospective cohort study in Bangladesh
BACKGROUND: Hyperinflammation-induced respiratory failure is a leading cause of mortality in COVID-19 infection. Immunosuppressants such as, Baricitinib and interleukin inhibitors are the drug-of-choice to suppress cytokine storm in COVID-19. Here, we compared the therapeutic safety and efficacy of...
Autores principales: | Hasan, Md Jahidul, Rabbani, Raihan, Anam, Ahmad Mursel, Huq, Shihan Mahmud Redwanul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903771/ https://www.ncbi.nlm.nih.gov/pubmed/35238257 http://dx.doi.org/10.1080/07853890.2022.2039958 |
Ejemplares similares
-
Aerosolized Plus Intravenous Polymyxin B Versus Colistin in the Treatment of Pandrug-Resistant Klebsiella Pneumonia-mediated Ventilator-Associated Pneumonia: A Retrospective Cohort Study in Bangladesh
por: Hasan, Md Jahidul, et al.
Publicado: (2023) -
The Susceptibility of MDR-K. Pneumoniae To Polymyxin B Plus Its Nebulised Form Versus Polymyxin B Alone in Critically Ill South Asian Patients
por: Hasan, Md. Jahidul, et al.
Publicado: (2021) -
Additional baricitinib loading dose improves clinical outcome in COVID-19
por: Hasan, Md Jahidul, et al.
Publicado: (2020) -
Secukinumab in severe COVID-19 pneumonia: Does it have a clinical impact?
por: Hasan, Md. Jahidul, et al.
Publicado: (2021) -
The Use of High Dose Eltrombopag in the Management of Sepsis-Associated Thrombocytopenia in Critically Ill Patients
por: Hasan, Md. Jahidul, et al.
Publicado: (2019)